Primary cutaneous lymphomas constitute a spectrum of diseases characterized by a clonal accumulation of lymphocytes in the skin. Cutaneous T-cell lymphomas of the cytotoxic phenotype, including CD8+ and CD56+ lymphomas are rare entities that have only been recently recognized and characterized. These lymphomas often show aggressive clinical course. We investigated the expression of HLA-G, IL-10 in conjunction with expression of HLA-G killer cell inhibitory receptor ligand ILT2 in 3 CD56+/CD4+ and 4 CD8+ cutaneous T-cell lymphomas. HLA-G expression was detected in 2 out of 3 lymphomas of CD56+/CD4+ type and in all lymphomas of CD8+ type. It is of note that CD56+/CD4+ lymphomas displayed stronger HLA-G reactivity. The expression of IL-10 matched the expression of HLA-G. Together with the expression of IL-10, HLA-G might be one of the factors accounting for the evasion of immunosurveillance thus contributing to aggressive phenotype of these lymphoma entities.
INTRODUCTION
Primary cutaneous lymphomas comprise a spectrum of heterogeneous diseases characterized by clonal accumulation of lymphocytes initially restricted to the skin 1 . Clonal T-cell populations of primary cutaneous T-cell lymphomas transcribe and secret T-helper (T h ) 2 cytokines like interleukin (IL) 10 2 .
Despite evidence of humoral and cellular anti-tumor immune response [3] [4] [5] , cutaneous T-cell lymphomas (CTCL) do eventually progress to systemic disease after a long history of quietness.
HLA-G represents a nonclassical HLA class Ib molecule whose expression is restricted to immunoprivileged sites, such as placenta 6, 7 . HLA-G negatively affects almost every aspect of human immunity, inhibiting allogeneic T-cell and NK-cell cytotoxicity as well as T-cell proliferative response 6, 7 . Ectopic expression of HLA-G in cancer is thought to enable tumor cells to escape host immunosurveillance 8 . Being expressed in advanced stage of the disease, HLA-G and IL-10 are molecules implicated in the progression of CTCL 2, 9 . 
MATERIAL AND METHODS

Patients
Following criteria applied to select the patients from Lymphoma Registry of the Department of Dermatology in Zurich were: diagnosis of lymphoproliferative disorder with cytotoxic phenotype with initial presentation in the skin; polymerase chain reaction evidence of T-cell receptor (TCR) rearrangement in biopsied lesion; no iatrogenic or HIV-induced immunosuppression. Patient's characteristics are presented in Table 1 .
Immunohistochemistry
Both paraffin-embedded as well as frozen material was available from all seven patients. Francisco, CA). Anti-human IL-10 (E-10) antibody was purchased from Santa Cruz Biotechnology, Inc., Santa Cruz, USA. Immunohistochemistry was performed using the alkaline phosphatase-antialkaline phosphatase (APAAP) technique, as previously described 9 . HLA-G staining was done according to the HLA-G workshop recommendations 13 .
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RESULTS AND DISCUSSION
Results of immunostaining for HLA-G and IL-10 are shown in the Table 1 indicates that the stainings were done on frozen tissue sections. † -deceased; GrB -granzyme B; * -positive, but not further specified; TIA1 -T-cell intracellular antigen 1. For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
